Skip to main content
. 2016 Jun 21;8:287–291. doi: 10.2147/CEOR.S71218

Figure 4.

Figure 4

Comparison of treating 1,000 women with advanced or recurrent cervical cancer with cisplatin/paclitaxel/bevacizumab to treating 18,598 women with ovarian cancer and carboplatin/paclitaxel after initial debulking surgery.